What,Huh? LOL 350 million dollars? for_Curing_Blindness
Did you remember to take out Ocata's current market
cap of 225 million?
That makes it only 125 million.
Over 20 years, when Human Embryonic Stem Cells
were first discovered, that's 6.25 a year, so what pilgrim?
Even if you start the clock at 2000, when the reverse
merger took place, and Two Moons KaCHING! was
transformed, thats about 8 1/3 mil a year.
What an Amazing Bargain For Curing Blindness!
Not to mention an entire suite of products, from the
underlying brand new field of technology,
and new branch of medicine.
It looks like the share price is holding steady in the
sixes. Ocata burns about $20 mil a year. If they
pull back, and batten down the hatches, and continue
with the first 20, phase 2 pivotal AMD patients, in
Q2, 2015, the data will take care of itself!
And Ocata has the money to do this already.
They have the doses already produced.
Phase 2 Data will bring money from all quarters,
all directions.
Comments From the CC 12Mar2015
PW_CC_12mar15(edited)
Our number one corporate objective for 2015 is the initiation of the next phase of our clinical trials.
We plan to initiate our Phase II trial for dry AMD in the second quarter of this[2015] year.
This Phase II study will include up to three cohorts of approximately 20 patients each.
We intend to complete the first cohort dosing during 2015.
Each of the three cohorts will be treated with a different immune suppression regimen to determine how much, if any, immune suppression is required.
PW_CC_12mar15(end)
